Graves Ophthalmopathy Clinical Trial
Official title:
The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession
The purpose of this study is to evaluate supramaximal rectus recession for strabismus in Grave's Ophthalmopathy
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | July 1, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of Grave's ophthalmopathy - angle of deviation more than 20° - clinically and biochemically euthyroid for at least 3 months; - a stable orthoptic examination for at least 3 months, for example no greater than five prism dioptre change in primary position and no greater than an 8° change in duction - monocular and mainly single extraocular muscle restricted motility Exclusion Criteria: - Patients with suppression, previously diagnosed and/or treated strabismus not related to the thyroid - best-corrected visual acuity (BCVA) less than 0.2 in one or both eyes |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative deviations | Postoperative deviations in the primary position were measured in prism diopters | 6 weeks | |
Primary | Postoperative deviations | Postoperative deviations in the primary position were measured in prism diopters | 3 months | |
Primary | Postoperative deviations | Postoperative deviations in the primary position were measured in prism diopters | 6 months | |
Secondary | binocular single vision | measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore. | 6 weeks | |
Secondary | binocular single vision | measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore. | 3 months | |
Secondary | binocular single vision | measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore. | 6 months | |
Secondary | stereoacuity | measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis. | 6 weeks | |
Secondary | stereoacuity | measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis. | 3 months | |
Secondary | stereoacuity | measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis. | 6 months | |
Secondary | ocular motility | evaluate the ocular motility with fixed visual field examination ,scaled from -4 to +4 | 6 weeks | |
Secondary | ocular motility | evaluate the ocular motility with fixed visual field examination,scaled from -4 to +4 | 3 months | |
Secondary | ocular motility | evaluate the ocular motility with fixed visual field examination,scaled from -4 to +4 | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
Not yet recruiting |
NCT06413043 -
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
|
N/A | |
Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT01999790 -
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
|
N/A | |
Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
Terminated |
NCT01114503 -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|
||
Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|